BridgeBio Pharma Inc. (BBIO) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for BridgeBio Pharma Inc. (BBIO:NASDAQ), powered by AI.

Current Price
$66.80
P/E Ratio
-17.6
Market Cap
12.8B
Sector
Healthcare
What is the BridgeBio Pharma Inc. stock price forecast?

BridgeBio Pharma Inc. is currently trading at $66.80. View real-time AI analysis on Alpha Lenz.

What is BridgeBio Pharma Inc. insider trading activity?

View the latest insider trading data for BridgeBio Pharma Inc. on Alpha Lenz.

What is BridgeBio Pharma Inc.'s P/E ratio?

BridgeBio Pharma Inc.'s P/E ratio is -17.6.

BridgeBio Pharma Inc.

NASDAQ · BBIO
$66.80-0.75(-1.11%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about BridgeBio Pharma Inc.'s future dividend policy...
Alpha Chat Insight

BridgeBio Pharma Inc. trades at a P/E of -17.6 (undervalued) with strong ROE of 40.8%. 3Y revenue CAGR of 86.3% highlights clear growth momentum.

Ask for details

Company Overview

BridgeBio Pharma Inc. is a cutting-edge biotechnology company focused on discovering, developing, and delivering transformative medicines for patients with genetic diseases. The company's primary purpose is to bridge the gap in medical research and bring breakthrough therapies to those with rare and often overlooked genetic disorders. By utilizing a targeted approach, BridgeBio Pharma Inc. works across multiple sectors including dermatology, oncology, cardiology, neurology, and endocrinology. The company partners with academic institutions, research organizations, and industry leaders to harness the latest scientific advancements in genomics and biotechnology. Established with a mission to translate genetic research into real-world medical solutions, BridgeBio Pharma Inc. plays a significant role in the biopharmaceutical market. It is heavily involved in the early and late stages of drug development, positioning itself as a key player in the quest to address unmet medical needs. This focus on genetic-centric therapies underlines its importance in the rapidly evolving landscape of biotechnology and personalized medicine.

CEODr. Neil Kumar Ph.D.
SectorHealthcare
IndustryBiotechnology
Employees725

Company Statistics

FY 2025

Profile

$12.79BMarket Cap
$502.08MRevenue
0.00Shares Out
725Employees

Margins

95.82%Gross
-100.85%EBITDA
-100.00%Operating
-145.89%Pre-Tax
-145.98%Net

Valuation

-17.65P/E
-6.13P/B
25.48EV/Sales
-27.84EV/EBITDA
-28.09P/FCF

Growth (CAGR)

86.30%Rev 3Yr
127.44%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-79.01%ROA
40.79%ROE
-59.75%ROIC

Financial Health

$570.12MCash & Cash Equivalents
$2.44BNet Debt
-145.08%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

BridgeBio Pharma Inc. (ticker: BBIO) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 725 employees. Market cap is $12.8B.

The current price is $66.8 with a P/E ratio of -17.65x and P/B of -6.13x.

ROE is 40.79% and operating margin is -100.00%. Annual revenue is $502M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
BridgeBio Pharma Inc. (BBIO) Stock Forecast 2026 $66.80 — Price, Financials & Analyst Targets | Alpha Lenz